Skip to main content

Advertisement

Table 5 Grade 3–4 toxicities per patient (all patients n = 40)

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

  Grade 3–4 haematologic toxicity
Group Neutropenia, no. pts (%) Thrombocytopenia, no. pts (%) Anemia, no. pts (%)
A - - 1 (2.5%)
B - - -
C 6 (15%) 8 (20%) 2 (5%)
  Grade 3–4 non-haematologic toxicity
Group Hepatic, n. pts (%) Mucositis, n. pts (%) Nausea/vomiting, n. pts (%)
A - - -
B - 1 (2.5%) -
C 2 (5%) - 2 (5%)